As the world is slowly, gradually, hopefully emerges from the shadow of COVID-19 there’s a unique opportunity to re-discover what matters most to patients.
The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen, more investment and better diagnostics may be needed, explains Ben Har
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
